ProQR Therapeutics N.V.
No enriched coverage for $PRQR in the last 7 days.
No SEC Form 4 filings for $PRQR in the last 30 days.
ProQR Therapeutics N.V. (Nasdaq: PRQR) has nominated Dr. Lykke Hinsch Gylvin, Chief Medical Officer at Boehringer Ingelheim, to its Board of Directors. Dr. Gylvin brings over 20 years of global leadership experience in drug development across various therapeutic areas. Her nomination will be submitted for shareholder approval at the company's upcoming Annual General Meeting.
ProQR Therapeutics has nominated Dr. Lykke Hinsch Gylvin, CMO of Boehringer Ingelheim, to its board of directors as an independent non-executive member, pending shareholder approval. This move aims to strengthen ProQR’s board with extensive global drug-development expertise, crucial as the company advances its Axiomer RNA editing pipeline. Dr. Hinsch Gylvin's experience is expected to bolster ProQR's long-term growth strategy and enhance investor confidence.
ProQR Therapeutics N.V. (NASDAQ:PRQR) has experienced a 28% share price drop in the last month, contributing to a 26% decline over the past year. The company's low price-to-sales (P/S) ratio of 9.4x, compared to an industry average of 12.4x, reflects investor concerns about its declining revenue, which fell by 13% last year. While analysts forecast 54% annual revenue growth for the next three years, this is significantly lower than the broader industry's 123% forecast, explaining the depressed P/S ratio and investor pessimism.
